Table 3 Small RNA-based therapeutics in clinical trials (adapted from[71])
Gene target | Drug type | Drug name | Clinical phase | Notes |
|---|---|---|---|---|
Bcl-2 | LNA-oligo | SPC2996 | I/II | CLL |
Immunoproteasome β-subunits LMP2, LMP7 and MECL1 | siRNA | Proteasome siRNA | I | Metastatic lymphoma |
PLK1 | siRNA | PLK SNALP | pre-clinical | Â |
M2 subunit of ribonucleotide reductase | siRNA | CALAA-01 | I | Solid tumors |
PKN3 | siRNA | Atu027 | I | Solid tumors |
KSP and VEGF | siRNA | ALN-VSP | I | Solid tumors |
Survivin | LNA-oligo | EZN3042 | I/II | Solid tumors |
HIF-1α | LNA-oligo | EZN2968 | I/II | Solid tumors |
Furin | shRNA | FANG vaccine | I | Solid tumors |
eiF-4E | LNA-oligo | elF-4E ASO | I | Solid tumors |
Survivin | LNA-oligo | Survivin ASO | II | Solid tumors |